多肽AP25与多西他赛联合用药对人乳腺癌裸鼠移植瘤的抑制活性研究  

Combination of polypeptide AP25and docetaxel in the treatment of breast cancer

作　　者：王佳艺[1] 何俊劲 郝静超 程昊冉 徐寒梅[1] 

机构地区：[1]中国药科大学多肽药物创制工程研究中心,江苏南京210009

出　　处：《中国药理学通报》2015年第9期1233-1238,共6页Chinese Pharmacological Bulletin

基　　金：国家高技术研究发展计划(863计划)资助项目(No2012AA020304);国家科技部"重大新药创制"科技重大专项(No 2014ZX09508007-001;2012ZX09103301-004);国家重点实验室培育计划(No SKLNMBZ201403)

摘　　要：目的检测多肽AP25与多西他赛联合使用治疗实验性乳腺癌的活性是否优于单用两种药物的活性,为临床合理用药提供依据。方法建立人乳腺癌MDA-MB-231裸鼠移植瘤模型,以多西他赛(10 mg·kg-1)和多西他赛(5 mg·kg-1)为阳性对照,观察AP25单用及与多西他赛联合应用对肿瘤生长的抑制作用,用金氏公式计算Q值,评价联合用药的作用效果。结果动物实验表明,AP25与多西他赛联合使用抑瘤率明显提高,AP25(20 mg·kg-1)与多西他赛(10 mg·kg-1)联合使用具有较明显的抑制MDA-MB-231肿瘤生长的作用,0.85<Q=0.99<1.15,联合作用为相加;AP25(20 mg·kg-1)与多西他赛(5 mg·kg-1)联合使用具有明显抑制MDA-MB-231肿瘤生长的作用,Q=1.18>1.15,联合作用为协同。结论多肽AP25与多西他赛联合用药明显抑制肿瘤生长,两种药物联合使用可以降低多西他赛的给药剂量,从而降低毒副作用。Aim To evaluate whether the combination of polypeptide AP25 and docetaxel is more efficient in treating experimental breast cancer,than either reagent used alone,and to offer suggestions for clinical use.Methods An experimental breast carcinoma model was set up to investigate the anti-tumor effects of AP25 and docetaxel combination. The Q value was caluculated by Guinness rules and the anti-tumor effects of the combination of polypeptide AP25 and docetaxel were evaluated. Results The treatment by the combination of polypeptide AP25 and docetaxel showed a better tumor inhibition rate. The combination of AP25 20 mg·kg- 1and docetaxel 10 mg·kg- 1significantly inhibited the tumor growth with 0. 85 Q = 1. 01 1. 15,showing an additive effect while the combination of AP25 20 mg·kg- 1and docetaxel 5 mg·kg- 1significantly inhibited the tumor growth with Q = 1. 18 1. 15,showing a synergistic effect. Conclusions The combination of AP25 and docetaxel can significantly inhibit the tumor growth with a synergistic effect and decrease the dose of chemotherapy.

关 键 词：AP25多西他赛 抗肿瘤多肽 乳腺癌 金氏公式 协同作用 联合给药 

分 类 号：R-332[医药卫生] R737.905